Browse by author
Lookup NU author(s): Emeritus Professor Pete Wright
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2019 The Author(s). Background: Many valuable biopharmaceutical and biotechnological proteins have been produced in Escherichia coli, however these proteins are almost exclusively localised in the cytoplasm or periplasm. This presents challenges for purification, i.e. the removal of contaminating cellular constituents. One solution is secretion directly into the surrounding media, which we achieved via the 'hijack' of the flagellar type III secretion system (FT3SS). Ordinarily flagellar subunits are exported through the centre of the growing flagellum, before assembly at the tip. However, we exploit the fact that in the absence of certain flagellar components (e.g. cap proteins), monomeric flagellar proteins are secreted into the supernatant. Results: We report the creation and iterative improvement of an E. coli strain, by means of a modified FT3SS and a modular plasmid system, for secretion of exemplar proteins. We show that removal of the flagellin and HAP proteins (FliC and FlgKL) resulted in an optimal prototype. We next developed a high-throughput enzymatic secretion assay based on cutinase. This indicated that removal of the flagellar motor proteins, motAB (to reduce metabolic burden) and protein degradation machinery, clpX (to boost FT3SS levels intracellularly), result in high capacity secretion. We also show that a secretion construct comprising the 5′UTR and first 47 amino acidsof FliC from E. coli (but no 3′UTR) achieved the highest levels of secretion. Upon combination, we show a 24-fold improvement in secretion of a heterologous (cutinase) enzyme over the original strain. This improved strain could export a range of pharmaceutically relevant heterologous proteins [hGH, TrxA, ScFv (CH2)], achieving secreted yields of up to 0.29 mg L-1, in low cell density culture. Conclusions: We have engineered an E. coli which secretes a range of recombinant proteins, through the FT3SS, to the extracellular media. With further developments, including cell culture process strategies, we envision further improvement to the secreted titre of recombinant protein, with the potential application for protein production for biotechnological purposes.
Author(s): Green CA, Kamble NS, Court EK, Bryant OJ, Hicks MG, Lennon C, Fraser GM, Wright PC, Stafford GP
Publication type: Article
Publication status: Published
Journal: Microbial Cell Factories
Year: 2019
Volume: 18
Issue: 1
Online publication date: 18/01/2019
Acceptance date: 08/01/2019
Date deposited: 12/02/2019
ISSN (print): 1475-2859
Publisher: BioMed Central Ltd.
URL: https://doi.org/10.1186/s12934-019-1058-4
DOI: 10.1186/s12934-019-1058-4
PubMed id: 30657054
Altmetrics provided by Altmetric
